New Analysis of Data Presented at AHA Regarding Effect of Effient on Cardiovascular Events in STEMI Patients According to Timing of PCI

An analysis of the TRITON-TIMI 38 trial presented today in an oral session at the American Heart Association Scientific Sessions meeting examined the effect of Effient® (prasugrel) on cardiovascular events compared to clopidogrel relative to the timing of percutaneous coronary intervention in acute coronary syndrome patients with ST-segment elevation myocardial infarction. At 15 months, primary PCI patients with STEMI had an 11 percent relative risk reduction in CV events, and secondary PCI patients had a 35 percent relative risk reduction with Effient compared to clopidogrel (HR 0.89, 95% CI 0.69-1.13; and HR 0.65, 95% CI 0.46-0.93, respectively). Absolute risk reduction for Effient compared to clopidogrel was 1.3 percent for the primary PCI group and 4.6 percent for the secondary PCI group. Daiichi Sankyo Company, Limited and Eli Lilly and Company

co-developed Effient, an oral antiplatelet agent discovered by Daiichi Sankyo and its Japanese research partner, Ube Industries, Ltd.